Experts say the emerging tech can dramatically accelerate advances in drug discovery, diagnostics and precision medicine.

Q4 2025 earnings call recap: 2026 revenue guidance, TearCare reimbursement milestone, OMNI growth outlook, margins and risks—read now.

The Triangle’s life sciences sector is in the midst of one of the most significant growth waves in its history. But as the ...

AICA currently supports auditing against 21 CFR Parts 11, 211, and 600, each mapped at the section and subsection levels.

Every life sciences company knows that patient safety is non negotiable, but the way safety is managed—and the value ...

Also in attendance is Sight Sciences, Inc. Chief Operating Officer, Alison Bauerlein. Earlier today, Sight Sciences, Inc. released its financial results for the fourth quarter ended December 31, 2025, ...

Gilead Sciences has agreed to buy the rest of development partner Arcellx in a deal that values the biotechnology company at about $7.8 billion at closing.

The Penn Museum and the Academy of Natural Sciences of Drexel University have discontinued their long-running summer camp ...

Following a difficult start in 2025, the ever-evolving life sciences segment recovered strongly in the latter half of the year.

Learn more about whether Exact Sciences Corporation or Avidity Biosciences, Inc. is a better investment based on AAII's A+ ...

Upcycle, swap and style sustainably with the Natural Sciences Council! Bring a tee or tote to revamp and learn how small ...

Thank you for participating in today's call. Presenting today are Sight Sciences Co-Founder and Chief Executive Officer, Paul Badawi; and Chief Financial Officer, Jim Rodberg. Also in attendance is ...